One of the main ingredient components of the blood flow support product is an enzyme produced from soy bean in Japan now patented in the USA UNDER THE USPTO
Confirming the effect on the fibrinolytic activity by the oral administration of NKCP (special type developed in a halotolerant culture bacillopeptidase F) 8 healthy participants between the ages of 20 and 60 took 500mg NKCP orally in enteric capsules, daily for 7 days. As a result, the euglobulin lysis time（ELT）was shorter from Day 4 and was shortened in all participants on Day 7. In addition, the same tendency was observed in the administration of 250mg per day. Secondly, in order to confirm the effect on the fluidity of whole blood by the oral administration of NKCP, 39-year-old healthy male took 1g NKCP orally in enteric capsules, after every meal for 14 days. As a result, the passage time for 100μl of heparinized whole blood through capillary was 46.7 seconds after Day 7 while the average time before the administration was 54.8 seconds. The results above imply that the oral administration of NKCP improves fibrinolytic activity and also controls thrombus formation.
1)Sumi,H,,Hamada,H,Tsushima,H.,Mihara, H.and-Muraki,H:A novel fibrimlytic enzyme(nattokinase)in the vegetab1e cheese Natto;atypica1and-popular soybeanfood inthe Japanese diet, Exprientia 43, 1110(1987)
2)Sumi,H.,Hamada,H,Nakanishi,K.and Hiratani, H.:Enhancement of the丘brino1ytic activity in plasma by ora1administration ofnattokinase, Acta Haematol., 84,139(1990)